Can CDK4/6 inhibitors cause fatal lung injury?

Expert Rev Anticancer Ther. 2019 Nov;19(11):917-919. doi: 10.1080/14737140.2019.1674651. Epub 2019 Oct 8.

Authors

Khalid A Jazieh¹, G Thomas Budd², Nancy Dalpiaz², Jame Abraham²

Affiliations

¹ Department of Internal Medicine, Cleveland Clinic Foundation, Cleveland, OH, USA.
² Department of Hematology and Medical Oncology, Taussig Cancer Center, Cleveland Clinic Foundation, Cleveland, OH, USA.

PMID: 31566017
DOI: 10.1080/14737140.2019.1674651

No abstract available

Keywords: Abemaciclib; Breast Cancer; Palbociclib; Pneumonitis; Toxicity.

Publication types

Editorial

MeSH terms

Aminopyridines / administration & dosage
Aminopyridines / adverse effects
Aminopyridines / pharmacology
Antineoplastic Agents / administration & dosage
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / pharmacology
Benzimidazoles / administration & dosage
Benzimidazoles / adverse effects
Benzimidazoles / pharmacology
Cyclin-Dependent Kinase 4 / antagonists & inhibitors
Cyclin-Dependent Kinase 6 / antagonists & inhibitors
Humans
Lung Diseases / chemically induced*
Piperazines / administration & dosage
Piperazines / adverse effects
Piperazines / pharmacology
Protein Kinase Inhibitors / administration & dosage
Protein Kinase Inhibitors / adverse effects*
Protein Kinase Inhibitors / pharmacology
Purines / administration & dosage
Purines / adverse effects
Purines / pharmacology
Pyridines / administration & dosage
Pyridines / adverse effects
Pyridines / pharmacology

Substances

Aminopyridines
Antineoplastic Agents
Benzimidazoles
Piperazines
Protein Kinase Inhibitors
Purines
Pyridines
abemaciclib
CDK4 protein, human
CDK6 protein, human
Cyclin-Dependent Kinase 4
Cyclin-Dependent Kinase 6
palbociclib
ribociclib